

SEATTLE, WA 98111-1208

United States Patent and Trademark Office



PAPER NUMBER

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

CONFIRMATION NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 10/056,998 01/25/2002 270/275US Mark P. Ohan 3516 EXAMINER 34055 06/24/2005 7590 PERKINS COIE LLP GHALI, ISIS A D **POST OFFICE BOX 1208**

ART UNIT

DATE MAILED: 06/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
Office Action Summary		10/056,998	OHAN ET AL.
		Examiner	Art Unit
		Isis Ghali	1615
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).			
Status			
1)⊠ Responsive to communication(s) filed on <u>15 April 2005</u> .			
2a)☐ This action is FINAL			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.			
Disposition of Claims			
 4) Claim(s) is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1,3-6,8 and 9 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 			
Application Papers			
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 			
Priority under 35 U.S.C. § 119			
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 			
Attachment(s)			
Notice of References Cited (P7 2) Notice of Draftsperson's Paten 3) Information Disclosure Statemer Paper No(s)/Mail Date		4) Interview Summary (Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	(PTO-413) te atent Application (PTO-152)

Application/Control Number: 10/056,998 Page 2

Art Unit: 1615

DETAILED ACTION

The receipt is acknowledged of applicants' request for extension of time, request for RCE, and amendment, all filed 04/15/2005.

Claims 1, 3-6, 8 and 9 are pending and included in the prosecution.

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 04/15/2005 has been entered.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 10/056,998 Page 3

Art Unit: 1615

prior art under 35 U.S.C. 103(a).

3. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g)

4. Claims 1, 3-6, 8 and 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,849,141 ('141) in view of the article "collagen-biomaterial for drug delivery" by Friess.

US '141 method for preparing formulation comprising collagen, solvent and glucose, said method comprising mixing of the ingredients (abstract). The formulation is cross-linked using UV irradiation or gamma irradiation (col.6, lines 48-50). The formulation is suitable for implantation and can take the shape of sheet-like (col.7, lines 1-5).

The reference does not teach sterilization by gamma irradiation, however, the reference teaches the desire to preserve and stabilize the formulation by adding preservatives and stabilizers (col.7, lines 11-13).

Friess teaches that gamma irradiation is the method of choice to sterilize collagen biomaterials mainly for its high efficacy and accurately controlled dose (page 121 of the article, paragraph 3.5.2).

Therefore, it would have been obvious to one having ordinary skill in the art at the time of the invention to provide formulation comprising collagen and glucose that is cross-linked by UV radiation, and instead of stabilizing and preserving the formulation using stabilizers or preservatives as disclosed by US '141 the skilled artisan would gamma irradiate the formulation as disclosed by Friess, motivated by the teaching of Friess that gamma radiation is the method of choice to sterilize collagen biomaterials mainly for its high efficacy and accurately controlled dose, with reasonable expectation of having formulation comprising collagen and glucose that is cross-linked with UV radiation and subsequently sterilized efficiently and accurately by gamma irradiation wherein the formulation is stable at storage and sterile when ready to use.

Response to Arguments

- 5. Applicant's arguments with respect to claims 1, 3-6, 8, and 9 have been considered but are moot in view of the new ground(s) of rejection.
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Isis Ghali whose telephone number is (571) 272-0595. The examiner can normally be reached on Monday-Thursday, 7:00 to 5:30.

Art Unit: 1615

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Isis Ghali Examiner Art Unit 1615

IG

